Sign Out
Paroxysmal Nocturnal Hemoglobinuria: ULTOMIRIS is indicated for the treatment of adult and pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH) who presents with clinical symptom(s) indicative of high disease activity; who are clinically stable after having been treated with eculizumab for at least the past 6 months.
Atypical Hemolytic Uremic Syndrome: ULTOMIRIS is indicated for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
Generalized Myasthenia Gravis: ULTOMIRIS is indicated as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
